3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
21
Gastrointestinal
21
Endocrine
21
CNS
4
Sarcoma
3
Lymphoid
2
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Conditions
Lymphoma, Non-Hodgkin
767
Lymphoma
713
Leukemia, Lymphocytic, Chronic, B-Cell
560
Lymphoma, Follicular
515
Lymphoma, Large B-Cell, Diffuse
440
Precursor Cell Lymphoblastic Leukemia-Lymphoma
331
Recurrence
317
Lymphoma, B-Cell
294
Neoplasms
261
Lymphoma, Mantle-Cell
251
Leukemia
231
Multiple Myeloma
189
Hodgkin Disease
179
Leukemia, Myeloid, Acute
178
Lymphoma, B-Cell, Marginal Zone
135
Lymphoma, T-Cell, Peripheral
119
Burkitt Lymphoma
105
Myelodysplastic Syndromes
101
Hematologic Neoplasms
100
Lymphoma, T-Cell, Cutaneous
88
Waldenstrom Macroglobulinemia
84
Leukemia, B-Cell
79
Lymphoma, T-Cell
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Lymphoproliferative Disorders
57
Hematologic Diseases
57
Melanoma
54
Carcinoma, Non-Small-Cell Lung
54
Breast Neoplasms
51
Mycosis Fungoides
49
Interventions
pasireotide
1
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Lymphoid
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled